SCHEMBL10049902

SCHEMBL10049902

Cc1ccn(C2CCCCC2)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 1/20 0.41
ALDH1A1 P00352 4/20 0.38
KDM4E B2RXH2 2/20 0.38
HSD17B10 Q99714 1/20 0.38
TSHR P16473 2/20 0.38
HPGD P15428 1/20 0.37
GAA P10253 2/20 0.34
ALOX15 P16050 1/20 0.34
MAPT P10636 2/20 0.33
HCAR1 Q9BXC0 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
GFER P55789 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
ATM Q13315 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
WDR5 P61964 1/20 0.33
TP53 P04637 1/20 0.33
NOS1 P29475 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10049903 0.98 SIGMAR1 (0.39) SIGMAR1ALDH1A1KDM4EHSD17B10TSHR
SCHEMBL16969326 0.94 SIGMAR1 (0.36) SIGMAR1ALDH1A1KDM4EHSD17B10TSHR
SCHEMBL15034177 0.90
SCHEMBL15448695 0.82 TP53 (0.33) ALDH1A1KDM4ETSHRGAAMAPT
SCHEMBL26157220 0.82 TP53 (0.33) ALDH1A1KDM4ETSHRGAAMAPT
SCHEMBL23712673 0.81 KDM4E (0.35) ALDH1A1KDM4ETSHRGAAMAPT
SCHEMBL1425947 0.81 CHRNB2 (0.41) ALDH1A1ALOX15MAPTTDP1MEN1
SCHEMBL17918656 0.81 FAAH (0.40) SIGMAR1HCAR1TP53
SCHEMBL17001832 0.81 GAA (0.41) SIGMAR1GAAALOX15SMN1; SMN2L3MBTL1
SCHEMBL12208791 0.81 NOS1 (0.35) ALDH1A1KDM4ETSHRGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024020458-A1 METHOD OF TREATING ORGAN DISEASES OR DISORDERS WITH ASK1 INHIBITORS Seal Rock Therapeutics, Inc. (US) 2024-01-25 WO disclosed
US-20170334912-A1 Purine Diones As Wnt Pathway Modulators AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2017-11-23 US disclosed
US-9499529-B2 Therapeutic uses of curcumin analogs for treatment of prostate cancer CALIFORNIA STATE UNIVERSITY, FRESNO (US) 2016-11-22 US disclosed
WO-2016131098-A1 SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME THE UNIVERSITY OF QUEENSLAND (AU) 2016-08-25 WO disclosed
EP-2116535-B1 GLUCOKINASE-ACTIVATING SUBSTANCE KYORIN SEIYAKU KK (JP) 2014-06-11 EP disclosed
US-8173649-B2 Glucokinase activator KYORIN PHARMACEUTICAL CO., LTD. (JP) 2012-05-08 US disclosed
US-8173649-B2 Glucokinase activator KYORIN PHARMACEUTICAL CO., LTD. (JP) 2012-05-08 US disclosed
US-7968573-B2 Hydrazide compound and pesticidal use of the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-06-28 US disclosed
US-20110071291-A1 HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME IKEGAMI HIROSHI 2011-03-24 US disclosed
US-20100016304-A1 GLUCOKINASE ACTIVATOR TEIJIN LIMITED (JP) 2010-01-21 US disclosed
US-20100016304-A1 GLUCOKINASE ACTIVATOR TEIJIN LIMITED (JP) 2010-01-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016304-A1 GLUCOKINASE ACTIVATOR GCK, GCKR, GALK1 SIGMAR1 2176/4885ALDH1A1 1662/4885KDM4E 3322/4885
US-20170334912-A1 Purine Diones As Wnt Pathway Modulators WNT1, WNT3A, CTNNB1 SIGMAR1 968/4885ALDH1A1 1166/4885KDM4E 3779/4885
US-20110071291-A1 HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME ACHE, H1-2, H1-0 SIGMAR1 2797/4885ALDH1A1 238/4885KDM4E 1084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.